🔬 Launching the REACT Trial: A Milestone in Arthritis Research
The University of Birmingham has unveiled a groundbreaking clinical trial known as REACT—REmission induction of Arthritis caused by Cancer ImmunoTherapy. This pioneering study addresses a critical gap in patient care for those undergoing immune checkpoint inhibitor (ICI) therapies, a class of drugs revolutionizing cancer treatment by unleashing the body's immune system against tumors. Announced on February 16, 2026, the trial is now open for recruitment and represents the first UK effort to rigorously test anti-tumor necrosis factor (anti-TNF) therapy as a frontline option for ICI-induced inflammatory arthritis (ICI-IA), commonly referred to as checkpoint inhibitor-induced arthritis or CPI-arthritis.
Leading the charge is Professor Benjamin Fisher, a Professor of Rheumatology at the University of Birmingham and Theme Lead for Inflammatory Arthritis within the NIHR Birmingham Biomedical Research Centre (BRC). With over £1 million in funding from the National Institute for Health and Care Research (NIHR), the trial will recruit 70 patients across multiple UK centres, running until August 2028. Delivered through the Birmingham Cancer Research UK Clinical Trials Unit, REACT promises to deliver evidence-based strategies that balance arthritis control with uninterrupted cancer therapy.
This initiative underscores the University of Birmingham's commitment to translational research, bridging laboratory discoveries to bedside applications. For academics and researchers eyeing opportunities in clinical trials, the university's robust ecosystem offers pathways into rheumatology and oncology collaborations—explore research jobs for similar impactful roles.
Demystifying Immune Checkpoint Inhibitors and Their Side Effects
Immune checkpoint inhibitors (ICIs) work by blocking proteins like PD-1, PD-L1, or CTLA-4 that act as brakes on the immune system, allowing T-cells to attack cancer cells more effectively. Drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo) have transformed outcomes for melanoma, lung cancer, and more, with survival rates doubling in some cases. However, this immune activation can backfire, triggering immune-related adverse events (irAEs) where the overzealous response attacks healthy tissues.
Joint inflammation, manifesting as arthritis-like symptoms, emerges in at least 5% of ICI-treated patients, with studies reporting incidences up to 7.2 per 100 person-years. Symptoms include painful, swollen joints, stiffness, and reduced mobility, severely impacting quality of life (QoL). Unlike traditional rheumatoid arthritis (RA), ICI-IA often persists post-ICI discontinuation and requires nuanced management to avoid compromising anti-cancer efficacy.
In the UK, where over 10,000 patients receive ICIs annually via the NHS, this side effect poses a growing challenge. Early intervention is key, yet current protocols lag due to limited randomized data.
The Burden of CPI-Arthritis: Statistics and Real-World Impact
CPI-arthritis disrupts daily life, with patients reporting inability to walk, climb stairs, or perform basic tasks. A systematic review highlights arthralgia in up to 43% and frank arthritis in 1-7%, but prospective data pegs it at 4-6%. In advanced non-small cell lung cancer cohorts, rheumatic irAEs affect 5-10%, correlating with fatigue and work absenteeism.
Quality-of-life metrics like the Health Assessment Questionnaire (HAQ) scores worsen significantly, and persistent cases lead to chronic disability. Economically, it strains NHS resources through extended hospital stays and polypharmacy. The REACT trial targets this by prioritizing remission—defined as no active arthritis and steroid-free status at six months.
- Prevalence: 5-7% of ICI patients
- Common cancers affected: Melanoma (higher risk), lung, renal
- Median onset: 2-3 months post-ICI initiation
- Persistence: Up to 50% beyond ICI cessation
Current Treatment Landscape: Steroids vs. Emerging Biologics
Standard care begins with oral corticosteroids like prednisolone (initial dose 10-20mg daily), tapered once controlled. While effective short-term, steroids carry risks: osteoporosis, diabetes, infections, and potential ICI interference at high doses. Escalation to disease-modifying antirheumatic drugs (DMARDs) like methotrexate or biologics occurs late, reserved for refractory cases.
Anti-TNF agents, such as adalimumab (Humira)—a fully human monoclonal antibody inhibiting TNF-alpha—excel in RA and psoriatic arthritis, achieving remission in 20-40% per EULAR guidelines. Observational data suggest efficacy in ICI-IA, but safety in ongoing ICI therapy remains unproven. REACT fills this void.
| Treatment | Mechanism | Pros | Cons |
|---|---|---|---|
| Prednisolone | Broad immunosuppression | Quick onset, cheap | Systemic side effects, ICI interaction risk |
| Adalimumab | TNF-alpha blockade | Targeted, steroid-sparing | Injections, cost, unproven in ICI context |
REACT Trial Design: A Rigorous Randomized Approach
REACT is a multicentre, randomized, open-label trial allocating patients 1:1 to prednisolone or adalimumab (40mg subcutaneous every two weeks). Treatments de-escalate upon control (DAS28-CRP <2.6) or escalate if failing after four weeks. Primary outcome: proportion achieving remission at six months. Secondary: arthritis activity (DAS28), HAQ, EQ-5D QoL, ICI interruptions, cancer progression-free survival (PFS), and overall survival (OS) at 12 months.
Eligibility includes adults with confirmed ICI-IA (synovitis >1 joint, exclusion of infection/malignancy), on/former ICI. Exclusions: active infection, prior anti-TNF. Sites span England, powered for 80% detection of 25% remission difference (alpha=0.05).
Step-by-step process:
- Screening: Rheumatology/oncology referral
- Randomization: Within 4 weeks of arthritis onset
- Initiation: Arm-specific therapy
- Monitoring: Monthly visits, labs/imaging
- Follow-up: 12 months
Behind the Scenes: University of Birmingham's Research Excellence
Professor Benjamin Fisher, chief investigator, brings expertise from NIHR BRC's inflammatory arthritis theme. Collaborators include Dr. Anna Rowe and Professor Andrew Filer. The trial leverages Birmingham's NIHR/Wellcome Trust Clinical Research Facility and UK Musculoskeletal Translational Research Collaboration.
The University of Birmingham ranks top for rheumatology research impact (REF 2021), with £3.5m recent J&J funding for personalized arthritis therapies. For aspiring lecturers or professors in medical research, lecturer jobs and professor jobs here offer world-class platforms.
Explore career advice at how to write a winning academic CV.
A Beacon of Hope: Rebecca Smith's Patient Story
Rebecca (Becky) Smith, treated at Queen Elizabeth Hospital Birmingham, embodies the trial's urgency. Diagnosed with ocular melanoma post-optician visit, her cancer metastasized to the liver. ICI immunotherapy halted progression but induced crippling arthritis: bedbound, stairless, heel-less. Enrolled in REACT's adalimumab arm, she reports: "My pain eased; I walk, work, live." Follow her at Instagram.
Her turnaround—from devastation to heels—highlights targeted therapy's promise.
Expected Impacts: Transforming Clinical Practice
If adalimumab outperforms, guidelines (NICE, BSR) may shift to early biologics, reducing steroid burdens and enhancing QoL. Cancer outcomes data will clarify ICI compatibility, potentially boosting adherence. Broader: cost savings via fewer escalations, precedents for other irAEs (colitis, pneumonitis).
- Patient benefits: Faster remission, mobility restoration
- Clinician tools: Evidence for shared decisions
- NHS efficiency: Optimized resource use
University of Birmingham's Pivotal Role in UK Medical Research
Birmingham's NIHR BRC drives £100m+ annual research, excelling in immunotherapy and rheumatology. Recent feats: immunotherapy failure mechanisms (2025), RA remission biomarkers. For postdocs or research assistants, view postdoc jobs or research assistant jobs.
Read more on Birmingham's immunology at Cancer Immunology Centre.
Getting Involved: Recruitment and Participation
Eligible patients: Contact react@trials.bham.ac.uk or Prof. Fisher (+44 121 371 3201). Sites include Queen Elizabeth Hospital. Researchers: Collaborate via Birmingham Clinical Trials Unit.
For higher ed professionals, rate experiences at Rate My Professor.
Future Horizons: Beyond REACT
Success could spawn trials for combo therapies, biomarkers predicting ICI-IA. Global registries (e.g., SITC irAE) may adopt findings. In UK higher ed, it bolsters research funding bids. Stay informed via higher ed jobs and career advice.
Optimism prevails: REACT may ensure patients thrive, not just survive. University jobs at Birmingham await innovators.
%20logo.jpg&w=128&q=75)
